Methods and compositions relating to OPRM1 DNA methylation for personalized pain management
The disclosure relates to methods for pain management in the perioperative context, particularly through the use of the DNA methylation status of the human OPRM1 gene as a biomarker for increased susceptibility to perioperative pain, and related methods and compositions.
1. A method for the inhibition of perioperative pain or an atypical opioid response in a human subject in need thereof, the method comprising
assaying, in vitro, a biological sample from a subject to determine a methylation status of at least one CpG site in the human mu-1 opioid receptor gene (OPRM1),
wherein the at least one CpG site in OPRM1 is selected from the group consisting of CpG sites 1, 3, 4, 9, 11, 13, 17, and 22 as defined in Table 4,
wherein a methylation status of “methylated” at the at least one CpG site identifies the subject as one who is susceptible to perioperative pain or an atypical opioid response, and
administering to the subject identified as susceptible to perioperative pain or an atypical opioid response a demethylating agent, an inhibitor of the repressor element-1 silencing transcription factor (REST) and/or a regimen of multimodal analgesia for perioperative pain management.
2. The method of claim 1 , wherein the perioperative pain is selected from the group consisting of preoperative pain, acute postoperative pain, and chronic postoperative pain.
3. The method of claim 2 , wherein the perioperative pain is chronic postoperative pain.
4. The method of claim 1 , wherein the at least one CpG site is selected from the group consisting of CpG sites 13 and 22 as defined in Table 4, and the pain is chronic postoperative pain.
5. The method of claim 1 , wherein the biological sample is a blood sample.
6. The method claim 1 , wherein the atypical opioid response is selected from the group consisting of opioid tolerance and hyperalgesia.
7. The method of claim 1 , wherein the demethylating agent or REST inhibitor is administered before or after a surgical procedure is performed on the subject.
8. The method of claim 1 , wherein the demethylating agent is selected from the group consisting of procaine, zebularine and decitabine, or a combination thereof.
9. The method of claim 8 , wherein the demethylating agent is zebularine, decitabine, or a combination thereof.
10. The method of claim 1 , wherein the patient is administered a regimen of multimodal analgesia for perioperative pain management.
11. The method of claim 10 , wherein the regimen of multimodal analgesia comprises administering to the subject one or more agents selected from the group consisting of acetaminophen, a nonsteroidal anti-inflammatory drug (NSAID), gabapentin, pregabalin, a TRPV1 agonist, an NMDA receptor antagonist, an alpha-2 agonist, a dual acting agent, transdermal fentanyl, a long acting local anesthetic, a cannabinoid, or a combination thereof.
12. The method of claim 11 , wherein the administering of the one or more agents is before or after a surgical procedure is performed on the subject.
13. The method of claim 11 , wherein the administering of at least one of the one or more agents is after a surgical procedure is performed on the subject.
14. The method of claim 1 , wherein the biological sample is assayed by a method comprising isolation of genomic DNA from the biological sample.
15. The method of claim 1 , wherein the biological sample is assayed by a method comprising pyrosequencing.
16. The method of claim 15 , wherein the pyrosequencing comprises two or more rounds of a polymerase chain reaction.
17. The method of claim 1 , wherein the subject is a female subject.
18. The method of claim 1 , wherein the subject is self-reported Caucasian or white.
19. The method of claim 11 , wherein the one or more agents is selected from the group consisting of capsaicin, ketamine, memantine, clonidine, dexmedetomidine, and tapentadol.